Stocks · News reference

C4 Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.

Aug 11, 2026, 4:58 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 11:34 AMBenzinga Newsdesk
C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of $(0.37) per share from
Read original at benzinga
CCCC
SEC EDGARAug 11, 2026, 11:14 AMSEC EDGAR
8-K filing — C4 Therapeutics, Inc. (CCCC)
Filed: 2026-08-11 AccNo: 0001628280-26-055490 Size: 238 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
CCCC
BenzingaJun 11, 2026, 11:12 AMBenzinga Newsdesk
C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated
Read original at benzinga
CCCC